Critical Contrast: Celsius (CELH) vs. Aquinox Pharmaceuticals (AQXP)

Celsius (NASDAQ: CELH) and Aquinox Pharmaceuticals (NASDAQ:AQXP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Insider & Institutional Ownership

6.2% of Celsius shares are held by institutional investors. Comparatively, 96.3% of Aquinox Pharmaceuticals shares are held by institutional investors. 49.0% of Celsius shares are held by company insiders. Comparatively, 2.7% of Aquinox Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Celsius and Aquinox Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celsius 0 0 2 0 3.00
Aquinox Pharmaceuticals 0 0 3 0 3.00

Celsius presently has a consensus target price of $7.50, suggesting a potential upside of 32.28%. Aquinox Pharmaceuticals has a consensus target price of $25.00, suggesting a potential upside of 86.85%. Given Aquinox Pharmaceuticals’ higher probable upside, analysts clearly believe Aquinox Pharmaceuticals is more favorable than Celsius.

Risk & Volatility

Celsius has a beta of -0.71, suggesting that its stock price is 171% less volatile than the S&P 500. Comparatively, Aquinox Pharmaceuticals has a beta of -15.98, suggesting that its stock price is 1,698% less volatile than the S&P 500.

Valuation and Earnings

This table compares Celsius and Aquinox Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Celsius $22.76 million 11.38 -$3.06 million ($0.09) -63.00
Aquinox Pharmaceuticals N/A N/A -$37.00 million ($1.93) -6.93

Celsius has higher revenue and earnings than Aquinox Pharmaceuticals. Celsius is trading at a lower price-to-earnings ratio than Aquinox Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Celsius and Aquinox Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celsius -10.37% -18.23% -12.52%
Aquinox Pharmaceuticals N/A -34.72% -32.69%

Summary

Celsius beats Aquinox Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Celsius Company Profile

Celsius Holdings, Inc. is engaged in the development, marketing, sale and distribution of functional calorie-burning fitness beverages under the Celsius brand name. The Company’s product range includes Sparkling Grape Rush, Sparkling Watermelon, Sparkling Orange, Sparkling Wild Berry, Sparkling Cola, Raspberry Acai Green Tea, Peach Mango Green Tea, Flo Fusion Orange and Flo Fusion Berry. The Company’s products are sweetened with sucralose, which is suitable for consumers whose sugar intake is restricted. The Company’s Celsius brand uses ingredients and supplements, such as green tea (EGCG), ginger, calcium, chromium, B vitamins and vitamin C. The Company outsources the manufacturing process to third-party co-packers. It provides co-packers with flavors, ingredient blends, cans and other raw materials for its beverages purchased by it from various suppliers. It sells Celsius brand across retail segments, which include supermarkets and convenience stores.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. Its product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. AQX-1125 is a SHIP1 activator that has demonstrated preliminary safety, anti-inflammatory potential and drug properties in multiple preclinical studies.

Receive News & Ratings for Celsius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsius and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply